Organon & Co. OGN
As ofNov 20, 2026, 2:48 PM EST
- YTD
- +93.93%
- 1 year
- +95.02%
5D +0.01 (+0.07%)
- Market cap
- 3.65B
- Revenue (ttm)
- 6.10B
- Profit margin
- 3.49%
- EPS (ttm)
- 0.78
- Shares out
- 262.62M
- P/E ratio
- 17.83
- Forward P/E
- 3.81
- Dividend
- 0.08 (0.58%)
- Ex-dividend date
- Nov 9, 2026
- YTD return
- +93.93%
- 1-year return
- +95.02%
- Volume
- 887.68K
- Avg volume
- 2.71M
- Open
- 13.91
- Previous close
- 13.91
- Day's range
- 13.90 – 13.91
- 52-week range
- 5.70 – 13.92
- Beta
- 1.49
- Price target
- 10.33 (-25.7%)
- Earnings date
- Feb 11, 2027
- 50-day average
- 13.77
- 200-day average
- 11.84
Key statistics
- Enterprise value
- 10.75B
- Price / sales
- 0.60
- Price / book
- 3.06
- Payout ratio
- 10.26%
- Revenue growth
- -1.70%
- Free cash flow
- 721.37M
- Total cash
- 1.46B
- Total debt
- 8.55B
- Return on equity
- 20.29%
- Short % of float
- 8.52%
Fundamental scorecard
12 of 25 checks passed on OGN’s reported financials
12of 25 checks passed
- Value 3 of 5
- Growth 1 of 5
- Profitability 4 of 5
- Financial health 1 of 5
- Dividend 3 of 5
Statements to Sep 30, 2026.
Analyst view
- Target (low)
- 8.00
- Target (mean)
- 10.33
- Target (high)
- 14.00
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell1
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 0.94645.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 0.92 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 0.88 | 0.94 | +0.06 | +6.82% |
| Jul 31, 2026 | Jun 30, 2026 | 0.85 | 0.85 | 0.00 | 0.00% |
| Apr 30, 2026 | Mar 31, 2026 | 0.83 | 0.71 | -0.12 | -14.46% |
| Feb 12, 2026 | Dec 31, 2025 | 0.73 | 0.63 | -0.10 | -13.70% |
| Nov 10, 2025 | Sep 30, 2025 | 0.93 | 1.01 | +0.08 | +8.60% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | down | Outperform | Neutral |
| Apr 28, 2026 | Piper Sandler | up | Underweight | Neutral |
| Feb 24, 2026 | Barclays | main | Underweight | Underweight |
| Dec 9, 2025 | Barclays | init | — | Underweight |
| Nov 11, 2025 | JP Morgan | main | Underweight | Underweight |
| Nov 11, 2025 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- organon.com
News
Your note
Sign in to keep a note on OGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI KEVIN | Chief Executive Officer | Purchase | May 4, 2025 | 282,731 |
| ARJONA FERREIRA JUAN CAMILO | Officer | Conversion of Exercise of derivative security | Nov 5, 2026 | 41,565 |
| COX CARRIE SMITH | Officer and Director | Purchase | Nov 11, 2025 | 0 |
| FALCIONE AARON | Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 101,431 |
| KARP DANIEL | Officer | Conversion of Exercise of derivative security | Mar 30, 2026 | 69,547 |
| MORRISSEY JOSEPH T JR | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 12, 2026 | 153,316 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.16% | 31,921,897 | 444.19M | Sep 29, 2026 |
| Pentwater Capital Management Lp | 7.68% | 20,180,000 | 280.80M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.85% | 15,353,306 | 213.64M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.54% | 11,916,620 | 165.82M | Sep 29, 2026 |
| FIL LTD | 4.00% | 10,504,377 | 146.17M | Sep 29, 2026 |
| State Street Corporation | 3.72% | 9,759,303 | 135.80M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 15,638,261 | 217.61M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 8,332,789 | 115.95M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 6,024,699 | 83.83M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.45% | 3,815,001 | 53.09M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 3,010,255 | 41.89M | Jun 29, 2026 |
| NexPoint Funds I-NexPoint Merger Arbitrage Fund | 1.03% | 2,705,080 | 37.64M | Jun 29, 2026 |
